Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology.

@article{Vanderveen2017AntiVascularEG,
  title={Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology.},
  author={Deborah K Vanderveen and Michele B Melia and Michael B. Yang and Amy K. Hutchinson and Lorri B Wilson and Scott R. Lambert},
  journal={Ophthalmology},
  year={2017},
  volume={124 5},
  pages={619-633}
}
PURPOSE To review the available evidence on the ocular safety and efficacy of anti-vascular endothelial growth factor (VEGF) agents for the treatment of retinopathy of prematurity (ROP) compared with laser photocoagulation therapy. METHODS A literature search of the PubMed and Cochrane Library databases was conducted last on September 6, 2016, with no… CONTINUE READING